Cargando…
Point estimation for adaptive trial designs I: A methodological review
Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic tendency for the estimate of treatment effect to deviate from its true value,” and states that it is desirable to obtain and report estimates of treatment effects that reduce or remove this bias. The conventional en...
Autores principales: | Robertson, David S., Choodari‐Oskooei, Babak, Dimairo, Munya, Flight, Laura, Pallmann, Philip, Jaki, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613995/ https://www.ncbi.nlm.nih.gov/pubmed/36451173 http://dx.doi.org/10.1002/sim.9605 |
Ejemplares similares
-
Point estimation for adaptive trial designs II: practical considerations and guidance
por: Robertson, David S., et al.
Publicado: (2023) -
Adaptive designs in clinical trials: why use them, and how to run and report them
por: Pallmann, Philip, et al.
Publicado: (2018) -
Medicines and Healthcare products Regulatory Agency’s “Consultation on proposals for legislative changes for clinical trials”: a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing
por: Law, Martin, et al.
Publicado: (2023) -
Correction: Medicines and Healthcare products Regulatory Agency’s “Consultation on proposals for legislative changes for clinical trials”: a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing
por: Law, Martin, et al.
Publicado: (2023) -
Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)